MedTrace Logo

Evaluation of the International Diffusion of the European Code Against Cancer Through Mobile Telephony

NCT05992792 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1990

Last updated 2023-08-15

No results posted yet for this study

Summary

We conducted an implementation research pilot study to assess the adoption, fidelity, appropriateness and acceptability on an intervention to effectively disseminate cancer prevention messages to the public throught a mHealth implementation strategy

Conditions

  • Prevention
  • Health Behavior

Interventions

BEHAVIORAL

App message

Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.

BEHAVIORAL

SMS message

Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.

BEHAVIORAL

Internet

Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.

BEHAVIORAL

Whithout internet

Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.

Sponsors & Collaborators

  • International Agency for Research on Cancer

    collaborator OTHER

  • Hospital Universitario Reina Sofia de Cordoba

    lead OTHER_GOV

Principal Investigators

  • Carolina Espina · World Health Organization

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-01-10
Completion
2022-07-10

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05992792 on ClinicalTrials.gov